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Background: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We con-
ducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province.
Methods: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in
Kandahar for minor ailments unrelated to polio were enrolled. After obtaining informed consent, we col-
lected venous blood and conducted neutralization assay to detect poliovirus neutralizing antibodies.
Results: A total of 420 children were enrolled and 409/420 (97%) were analysed. Seroprevalence to polio-
virus type 1 (PV1) was 97% and 100% in the younger and older age groups respectively; it was 71% and
91% for PV2; 93% and 98% for PV3. Age group (RR = 3.6, CI 95% = 2.2–5.6) and place of residence outside of
Kandahar city (RR = 1.8, CI 95% = 1.2–2.6) were found to be significant risk factors for seronegativity.
Conclusions: The polio eradication program in Kandahar achieved high serological protection, especially
against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of
live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-
requisite for achieving poliovirus eradication.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
During 2017, cases of poliomyelitis caused by wild poliovirus
type 1 (WPV1) were detected only in Afghanistan (14 cases) and
Pakistan (8 cases) where endemic WPV1 circulation still persists
[1]. In this period, 7/14 (50%) cases of poliomyelitis in Afghanistan
were reported from Kandahar province. Wild poliovirus type 2 has
been declared eradicated; and wild poliovirus type 3 has not been
detected anywhere in the world since 2012 [2,3].
To complete WPV1 eradication, the Global Polio Eradication Ini-
tiative (GPEI) strives to strengthen routine immunization programs
and conducts poliovirus vaccine immunization campaigns to raise
population immunity to a level sufficient for interruption of polio-
virus circulation. In high-risk areas, such as Kandahar province of
Afghanistan, these campaigns are conducted on an almost monthly
basis. Despite the sustained efforts, however, WPV1 continues to
circulate [4]. In some instances, the security situation in Afghani-
stan limits vaccination teams from reaching high-risk populations;
however, suboptimal campaign coverage in areas with no security
limitations also contributes to continued circulation of WPV1.
Recent population movements between Pakistan and Afghanistan
further contributed to the risk of transmission of WPV1.
In April 2016, the World Health Organization (WHO) imple-
mented a worldwide switch from trivalent oral poliovirus vaccine
(tOPV) to a bivalent OPV (bOPV) removing live poliovirus serotype
2 from global use [5]. Inactivated poliovirus vaccine (IPV) was
introduced to routine immunization programs prior to the switch.
In addition to IPV use in routine immunization, this vaccine is also
occasionally used in vaccination campaigns to accelerate eradica-
tion of WPV1 or to control outbreaks of wild or vaccine-derived
polioviruses [6]. This was the case in Kandahar where an IPV vac-
cination campaign was carried out in the end of 2016.
Surveys of seroprevalence of anti-polio antibodies have been
carried out in many countries as a tool for program performance
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evaluation and to assess population immunity in targeted age
groups and areas of high risk for poliovirus transmission [7–11].
In Afghanistan, the polio eradication program has focused on con-
ducting immunization campaigns; in the year preceding this sur-
vey (June 2016-June 2017), there had been 12 campaigns
targeting children below 5 years of age with bOPV; and one cam-
paign in Kandahar with IPV. The estimated routine immunization
coverage with the third OPV dose was 60% in both 2015 and
2016; and it was 65% with IPV in 2016 which was the first year
after introduction of this vaccine into routine immunization sched-
ule [12]. The routine immunization schedule in Afghanistan
includes OPV administered at birth, 6, 10, and 14 weeks of age;
and IPV administered at 14 weeks of age.
We conducted an anti-polio antibody serological survey among
children visiting Mirwais Regional Hospital in Kandahar, Afghani-
stan. This state-run hospital is a secondary care referral hospital
which predominantly serves the population of Kandahar province,
however; due to its good reputation, patients from other areas of
the country often seek medical care in this hospital.
2. Methods
This was a facility-based survey among children in two age
groups: 6–11 months and 36–48 months. Children of target age
groups visiting Mirwais Regional Hospital for polio-unrelated
minor ailments and accompanied by an adult primary care giver
(in most instances a parent) were eligible for enrolment if consent
from child’s adult primary care giver was obtained. Children with
any severe acute or chronic illness requiring immediate medical
attention were excluded. The enrolment and sample collection
were carried out between June 1 and July 15, 2017.
Survey teams collected data on key indicators related to socio-
economic status and immunization history. Vaccination history for
OPV and IPV received through routine immunization was assessed
from vaccination cards when available or by parental recall if cards
were not available. The number of OPV or IPV doses received
through campaigns was always obtained by parental recall as no
documentation exists.
Trained phlebotomists collected 2 mL of peripheral blood using
standard venepuncture technique. After clotting and centrifuga-
tion, serum was separated and transferred to the Centers for Dis-
ease Control and Prevention in Atlanta, USA, for performance of
neutralization assays [13]. Seropositivity was defined as reciprocal
titers of poliovirus neutralizing antibodies >8 [8].
We calculated a required sample size in each age group assum-
ing seroprevalence of 90%, error margin of ±5%, alpha = 0.05, and a
power of at least 80%. The sample was further inflated by approx-
imately 10% to account for potential non-consent or for those chil-
dren in whom the blood sample was not obtained or was obtained
in insufficient quantity, which resulted in the final sample size of
205 children in each age group.
Analysis was performed using STATA version 12. Frequencies
and percentages were calculated for categorical variables. For sero-
prevalence, percentages with 95% CI were reported. Medians with
95% confidence intervals were reported for reciprocal antibody
titers using the bootstrap method.
This study received approval from the Ethical Review Commit-
tees of the World Health Organization, Aga Khan University, and
National Bioethics Committee of the Government of Pakistan, and
from the Afghani Institutional Review Board of the Ministry of Pub-
lic Health.
3. Results
There were 420 children whose parents consented to partici-
pate in the study. We obtained 418/420 (100%) blood samples; in
two children the venepuncture was unsuccessful. Of these samples
409/418 (98%) were received by CDC with sufficient quantity of
sera and were analysed. We report results from these 409 children,
including 200 in the 6–11 month-old group and 209 in the 36–48
month-old group.
Table 1 shows demographic indicators, residence, and vaccina-
tion history of the study population. Of note, there were 34% girls
among the enrolled children; the median age in the 6–11 month-
old age group was 10 months; 15% of the enrolled children resided
outside of Kandahar province; and 41% outside of Kandahar Dand
(urban) district. The retention of vaccination card was 96% and
the total doses of OPV received were 11 and 30 in the younger
and older age groups, respectively; 90% of children in both age
groups reported receiving at least one IPV dose.
Seroprevalence to PV1 was 97% and 100% in the younger and
older age groups respectively; it was 71% and 91% for PV2; 93%
and 98% for PV3 (Fig. 1). In the younger age group, the median
Table 1
Demographic indicators, residence, and vaccination history of the study population.
6–11
months
36–48
months
Total
n = 200 n = 209 N = 409
Gender female 71/200
(36%)
67/209
(32%)
138/
409
(34%)
Mean age (months) 10 42 27
Province of Residence
Kandahar 166/
200
(83%)
180/
209
(86%)
346/
409
(85%)
Hilmand 18/200
(9%)
19/209
(9%)
37/409
(9%)
Uruzgan 7/200
(4%)
2/209
(1%)
9/409
(2%)
Zabul 4/200
(2%)
3/209
(1%)
7/409
(2%)
Other 5/200
(3%)
5/209
(3%)
10/409
(2%)
District of residence (PROVINCE)
Dand (KANDAHAR) 109/
200
(55%)
133/
209
(64%)
242/
409
(59%)
Zheray (KANDAHAR) 21/200
(11%)
13/209
(6%)
34/409
(8%)
Panjwayi (KANDAHAR) 14/200
(7%)
15/209
(7%)
29/409
(7%)
Arghandab (KANDAHAR) 11/200
(6%)
14/209
(7%)
25/409
(6%)
Lashkargah (HILMAND) 9/200
(5%)
6/209
(3%)
15/409
(4%)
Other 36/200
(18%)
28/209
(13%)
64/409
(16%)
Vaccination card available 196/
200
(98%)
198/
209
(95%)
394/
409
(96%)
Total OPV doses received from routine
immunization and campaigns (mean)
11 30 21
Zero OPV doses received 1/200
(1%)
0/209
0%
1/409
(0%)
<3 OPV doses received 3/200
(2%)
1/209
(0%)
3/409
(1%)
Received POL 3 in routine immunization 172/
200
(86%)
185/
209
(89%)
357/
409
(87%)
IPV received (at least one dose) 180/
200
(90%)
188/
209
(90%)
368/
409
(90%)
OPV received during last campaign 185/
200
(93%)
197/
209
(94%)
382/
409
(93%)
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reciprocal titers were 1:1152, 1:90, and 1:576 for PV1, 2, and 3
respectively; they were 1:1152, 1:288, and 1:910 in the older age
group (Fig. 2). For PV2 the difference in seroprevalence between
the younger and older age groups reached significance (p < 0.001)
; for PV1 and PV3 it did not (p > 0.05).
We performed univariate analysis of risk factors for seronega-
tivity for at least one PV serotype. Young age was a significant risk
factor for seronegativity (RR = 3.6, CI 95% = 2.2–5.6). Residing out-
side of Kandahar province as well as outside of Kandahar Dand dis-
trict were significant risk factors for seronegativity (RR = 1.8, CI
95% = 1.2–2.6, RR = 1.5, CI 95% = 1.1–2.0), respectively, for province
and district. History of not receiving IPV failed to reach significance
as a risk factor for seronegativity (RR = 1.15, CI 95% = 0.7–1.4). In
our sample, gender was not a risk factor for seronegativity (RR =
1.14, CI 95% = 0.6–1.3). We have not analysed history of OPV in
relation to seronegativity because we did not have information
regarding OPV type (trivalent or bivalent).
4. Discussion
In our sample the seroprevalence was overall very high, exceed-
ing 95% for PV1 and 90% for PV3. Children in the younger age group
were born after the withdrawal of tOPV and therefore their only
opportunity to gain PV2 immunity was through administration of
IPV. These younger children could have received one IPV dose as
part of their routine immunization program at the age of 14 weeks,
or as part of the IPV campaign targeting children between 4
months and 5 years of age carried out at the end of 2016 in Kanda-
har. Previous studies have demonstrated that the seroconversion
rate varies with age of administration: if IPV is administered early,
maternal antibodies interfere with seroconversion; if administered
at 4 months of age, the seroconversion after one IPV dose was 31–
62% for PV2 [14]; and seroconversion after 2 IPV doses was close to
100% for PV2 [15]. In our sample, young children had 71% PV2 sero-
prevalence indicating that the vast majority received at least one
IPV dose. PV2 seroprevalence among the children in the higher
age group was 91%; this is because these children had been vacci-
nated with tOPV prior to tOPV withdrawal in May 2016. In our
study the previous history of IPV was not found to be significantly
associated with PV2 seropositivity. This is probably due to the fact
that IPV doses received through vaccination campaign were not
recorded in vaccination cards.
Children from Kandahar province had higher seroprevalence
than children from elsewhere; however, this was mostly a result
of the PV2 immunity gap in the younger children residing outside
of Kandahar and who were not targeted by the IPV campaign. In
general, in this study, the reported vaccination history was a poor
proxy of seropositivity.
Our study had some limitations. Due to security concerns, we
could not carry out a community survey but rather only a
facility-based one. We are unable to determine whether the
97%
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100%
91%
98%
50%
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Fig. 1. Prevalence of anti-polio antibodies (% positive and 95% confidence interval).
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Fig. 2. Median reciprocal titers and 95% confidence intervals (PV1, 2, 3: Poliovirus serotype 1m2 and 3).
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children visiting Mirwais hospital were representative of general
population, at least the population in Kandahar. The reported
immunization coverage and rate of retention of immunizations
card in our sample is higher than the national estimate and could
point to the study population being from a more privileged back-
ground. In addition, most of the children in the 6–11 moth-old
group were >9 months old which may have resulted in higher sero-
prevalence estimate for this age group.
Our results indicate that the polio program in Kandahar was
able to achieve high population immunity and high vaccination
coverage with the newly introduced IPV. However, despite of the
high seroprevalence for PV1, low level transmission of PV1 contin-
ued in Kandahar as evidenced by two newly reported cases of
WPV1 in 2018 [1]. This may indicate that pockets of under-
vaccinated populations persist. In order to finally achieve polio-
virus eradication, it is important to maintain high program quality
reaching all children with both poliovirus vaccines.
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